budesonide MMX
Selected indexed studies
- ** (, 2017) [PMID:29356466]
- Budesonide MMX: efficacy and safety profile in the treatment of ulcerative colitis. (Expert Rev Gastroenterol Hepatol, 2019) [PMID:31106602]
- Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety. (Ther Clin Risk Manag, 2021) [PMID:33854320]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- PMID:29356466 (2017) pubmed
- Budesonide MMX: efficacy and safety profile in the treatment of ulcerative colitis. (2019) pubmed
- Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety. (2021) pubmed
- A safety evaluation of budesonide MMX for the treatment of ulcerative colitis. (2018) pubmed
- Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. (2015) pubmed
- Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis. (2015) pubmed
- Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. (2014) pubmed
- The role of Budesonide-MMX in active ulcerative colitis. (2014) pubmed
- Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. (2019) pubmed
- Practical management of mild-to-moderate ulcerative colitis: an international expert consensus. (2024) pubmed